(firstQuint)Safety and Tolerability of MEDI3506 in Healthy Subjects and in Subjects With Chronic Obstructive Pulmonary Disease.

 This is a Phase 1, randomised, blinded, placebo controlled, study designed to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity response to single and multiple doses of MEDI3506 administered by either SC or IV routes.

 Part I: Single Ascending Doses in Healthy Subjects with a History of Mild Atopy Part II: Multiple Ascending Doses in Subjects with GOLD I-II COPD.

 Safety and Tolerability of MEDI3506 in Healthy Subjects and in Subjects With Chronic Obstructive Pulmonary Disease@highlight

This is a Phase 1, randomised, blinded, placebo controlled, study designed to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity response to single and multiple doses of MEDI3506.

